1. Complete biosynthesis of QS-21 in engineered yeast.
- Author
-
Liu Y, Zhao X, Gan F, Chen X, Deng K, Crowe SA, Hudson GA, Belcher MS, Schmidt M, Astolfi MCT, Kosina SM, Pang B, Shao M, Yin J, Sirirungruang S, Iavarone AT, Reed J, Martin LBB, El-Demerdash A, Kikuchi S, Misra RC, Liang X, Cronce MJ, Chen X, Zhan C, Kakumanu R, Baidoo EEK, Chen Y, Petzold CJ, Northen TR, Osbourn A, Scheller H, and Keasling JD
- Subjects
- Biosynthetic Pathways genetics, Drug Design, Enzymes genetics, Enzymes metabolism, Plants enzymology, Plants genetics, Plants metabolism, Structure-Activity Relationship, Adjuvants, Immunologic biosynthesis, Adjuvants, Immunologic chemistry, Adjuvants, Immunologic genetics, Adjuvants, Immunologic metabolism, Metabolic Engineering methods, Saccharomyces cerevisiae cytology, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae metabolism, Saponins biosynthesis, Saponins chemistry, Saponins genetics, Saponins metabolism
- Abstract
QS-21 is a potent vaccine adjuvant and remains the only saponin-based adjuvant that has been clinically approved for use in humans
1,2 . However, owing to the complex structure of QS-21, its availability is limited. Today, the supply depends on laborious extraction from the Chilean soapbark tree or on low-yielding total chemical synthesis3,4 . Here we demonstrate the complete biosynthesis of QS-21 and its precursors, as well as structural derivatives, in engineered yeast strains. The successful biosynthesis in yeast requires fine-tuning of the host's native pathway fluxes, as well as the functional and balanced expression of 38 heterologous enzymes. The required biosynthetic pathway spans seven enzyme families-a terpene synthase, P450s, nucleotide sugar synthases, glycosyltransferases, a coenzyme A ligase, acyl transferases and polyketide synthases-from six organisms, and mimics in yeast the subcellular compartmentalization of plants from the endoplasmic reticulum membrane to the cytosol. Finally, by taking advantage of the promiscuity of certain pathway enzymes, we produced structural analogues of QS-21 using this biosynthetic platform. This microbial production scheme will allow for the future establishment of a structure-activity relationship, and will thus enable the rational design of potent vaccine adjuvants., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF